Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARK3 | P27448 | 4/20 | 0.76 |
| ▸ | CAMK2B | Q13554 | 4/20 | 0.76 |
| ▸ | MARK2 | Q7KZI7 | 4/20 | 0.76 |
| ▸ | HIPK2 | Q9H2X6 | 4/20 | 0.76 |
| ▸ | GSK3B | P49841 | 3/20 | 0.76 |
| ▸ | MINK1 | Q8N4C8 | 3/20 | 0.76 |
| ▸ | SRPK1 | Q96SB4 | 3/20 | 0.76 |
| ▸ | NEK4 | P51957 | 3/20 | 0.76 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 0.76 |
| ▸ | CDC7 | O00311 | 2/20 | 0.76 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.76 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.76 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.76 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.76 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 0.76 |
| ▸ | EEF2K | O00418 | 2/20 | 0.76 |
| ▸ | AXL | P30530 | 2/20 | 0.76 |
| ▸ | CAMK2G | Q13555 | 2/20 | 0.76 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.76 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4168918 | 0.88 | MARK3 (0.59) | MARK3CAMK2BMARK2HIPK2GSK3B | |
| SCHEMBL2201257 | 0.86 | MARK3 (1.00) | MARK3CAMK2BMARK2HIPK2GSK3B | |
| SCHEMBL2205324 | 0.86 | MARK3 (0.84) | MARK3CAMK2BMARK2HIPK2GSK3B | |
| SCHEMBL2206423 | 0.83 | MARK3 (0.94) | MARK3CAMK2BMARK2HIPK2GSK3B | |
| SCHEMBL2204731 | 0.83 | MARK3 (0.81) | MARK3CAMK2BMARK2HIPK2GSK3B | |
| SCHEMBL2204748 | 0.81 | MARK3 (0.90) | MARK3CAMK2BMARK2HIPK2GSK3B | |
| SCHEMBL2204644 | 0.81 | MARK3 (0.89) | MARK3CAMK2BMARK2HIPK2GSK3B | |
| SCHEMBL2205257 | 0.79 | MARK3 (0.78) | MARK3CAMK2BMARK2HIPK2GSK3B | |
| SCHEMBL2204975 | 0.78 | MARK3 (0.85) | MARK3CAMK2BMARK2HIPK2GSK3B | |
| SCHEMBL2206322 | 0.78 | MARK3 (0.71) | MARK3CAMK2BMARK2HIPK2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3243814-B1 | 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS | ABBVIE INC (US) | 2018-10-17 | — | — | EP | claimed |
| EP-3243814-A1 | 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS | AbbVie Inc. (US) | 2017-11-15 | — | — | EP | claimed |
| US-9359296-B2 | 7-substituted indole Mcl-1 inhibitors | ABBVIE INC. (US) | 2016-06-07 | — | — | US | claimed |
| US-20150284328-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBVIE INC (US) | 2015-10-08 | — | — | US | claimed |
| US-20140051683-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBVIE INC. (US) | 2014-02-20 | — | — | US | claimed |
| EP-2134684-A2 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | Abbott Laboratories (US) | 2009-12-23 | — | — | EP | claimed |
| US-20090054402-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | US | claimed |
| WO-2008131000-A2 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | WO | claimed |
| EP-3243814-B1 | 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS | ABBVIE INC (US) | 2018-10-17 | — | — | EP | disclosed |
| EP-3243814-A1 | 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS | AbbVie Inc. (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2134684-B1 | 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS | ABBVIE INC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-9359296-B2 | 7-substituted indole Mcl-1 inhibitors | ABBVIE INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150284328-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBVIE INC (US) | 2015-10-08 | — | — | US | disclosed |
| US-9035047-B2 | 7-substituted indole Mcl-1 inhibitors | ABBVIE INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20140051683-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBVIE INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8445679-B2 | 7-substituted indole MCL-1 inhibitors | ABBVIE INC. (US) | 2013-05-21 | — | — | US | disclosed |
| EP-2134684-A2 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | Abbott Laboratories (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090054402-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2008131000-A2 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051683-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, API5 | MARK3 2332/4885CAMK2B 812/4885MARK2 3464/4885 |
| US-20150284328-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, API5 | MARK3 2332/4885CAMK2B 812/4885MARK2 3464/4885 |
| US-20090054402-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, API5 | MARK3 2332/4885CAMK2B 812/4885MARK2 3464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.